[HTML][HTML] Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged≥ 50 years: week 48 pooled results from the …
S Walmsley, DE Smith, M Górgolas, PE Cahn… - AIDS Research and …, 2024 - Springer
Background As the population of people with HIV ages, concerns over managing age-
related comorbidities, polypharmacy, immune recovery, and drug-drug interactions while …
related comorbidities, polypharmacy, immune recovery, and drug-drug interactions while …
Efficacy and safety of switching to the 2-drug regimen dolutegravir/lamivudine versus continuing a 3-or 4-drug regimen for maintaining virologic suppression in adults …
Background In TANGO, switching to dolutegravir/lamivudine (DTG/3TC) demonstrated long-
term noninferior efficacy vs continuing tenofovir alafenamide–based regimens in treatment …
term noninferior efficacy vs continuing tenofovir alafenamide–based regimens in treatment …
[HTML][HTML] Real-Life Experience on Dolutegravir and Lamivudine as Initial or Switch Therapy in a Silver Population Living with HIV
M Mazzitelli, L Sasset, S Gardin, D Leoni, M Trunfio… - Viruses, 2023 - mdpi.com
Background: Clinical trials and real-life studies have granted the efficacy and safety of
dolutegravir and lamivudine (DTG/3TC) in naïve and experienced people living with HIV …
dolutegravir and lamivudine (DTG/3TC) in naïve and experienced people living with HIV …
Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people living with HIV-1 aged over 65 years
L Calza, V Colangeli, G Legnani, S Cretella… - AIDS Research and …, 2024 - liebertpub.com
Clinical trials of dual regimen dolutegravir/lamivudine (DOL/3TC) demonstrated potent
efficacy and favorable safety in both antiretroviral therapy-naïve and-experienced patients …
efficacy and favorable safety in both antiretroviral therapy-naïve and-experienced patients …
[HTML][HTML] Real-World Effectiveness of Dolutegravir/Lamivudine in People With HIV-1 in Test-and-Treat Settings or With High Baseline Viral Loads: TANDEM Study …
P Benson, J Kuretski, C Donovan, G Harper… - Infectious Diseases and …, 2024 - Springer
Abstract Introduction Dolutegravir/lamivudine (DTG/3TC) was first approved by the US Food
and Drug Administration in 2019 for the treatment of antiretroviral therapy (ART)-naive …
and Drug Administration in 2019 for the treatment of antiretroviral therapy (ART)-naive …
[HTML][HTML] Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy–naive adults with HIV-1 infection
P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz… - Aids, 2022 - journals.lww.com
Objective: To assess efficacy and safety of dolutegravir (DTG)+ lamivudine (3TC) vs. DTG+
tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naive adults with HIV-1 in …
tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naive adults with HIV-1 in …
Switching to Dolutegravir/Lamivudine Two-Drug Regimen: Durability and Virologic Outcomes by Age, Sex, and Race in Routine US Clinical Care
G Pierone Jr, L Brunet, JS Fusco… - HIV/AIDS-Research …, 2024 - Taylor & Francis
Purpose Two-drug regimens (2DR) may address drug–drug interactions and toxicity
concerns. Dolutegravir/lamivudine (DTG/3TC) 2DR was approved in the US for both …
concerns. Dolutegravir/lamivudine (DTG/3TC) 2DR was approved in the US for both …
Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks …
J Rojas, E de Lazzari, E Negredo, P Domingo… - The Lancet …, 2021 - thelancet.com
Background Simplified antiretroviral therapy (ART) regimens are desirable for people with
HIV. We investigated the efficacy and safety of switching from triple ART to dual dolutegravir …
HIV. We investigated the efficacy and safety of switching from triple ART to dual dolutegravir …
Switching to the 2-drug regimen of dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC) is non-inferior to continuing a 3-drug regimen through 24 weeks …
JM Llibre, C Alves, CY Cheng, O Osiyemi… - Journal of the …, 2021 - go.gale.com
Background: Long-term non-inferior efficacy of the 2-drug regimen (2DR) DTG/3TC
compared with 3/4-drug regimens (3/4DRs) has been demonstrated in treatment-naive …
compared with 3/4-drug regimens (3/4DRs) has been demonstrated in treatment-naive …
1265. Effectiveness and Durability of Dolutegravir (DTG)-Based Regimens in Older People Living with HIV (PLWH) from the Veterans Aging Cohort Study (VACS)
L Yan, C Henegar, K Gordon, C Hicks… - Open Forum …, 2022 - academic.oup.com
Background HIV management among older people living with HIV (PLWH) may be
complicated by the presence of multiple comorbidities and polypharmacy. This study …
complicated by the presence of multiple comorbidities and polypharmacy. This study …